Abstract
Background In October 2020 SARS-CoV-2 seroprevalence among hospital healthcare workers (HCW) of two Irish hospitals was 15% and 4.1% respectively. We compare seroprevalence in the same HCW population six months later, assess changes in risk factors for seropositivity with progression of the pandemic and serological response to vaccination.
Methods All staff of both hospitals (N=9038) were invited to participate in an online questionnaire and SARS-CoV-2 antibody testing in April 2021. We measured anti-nucleocapsid and anti-spike antibodies. Frequencies and percentages for positive SARS-CoV-2 antibodies were calculated and adjusted relative risks for participant characteristics were calculated using multivariable regression analysis.
Results 5085 HCW participated. Seroprevalence increased to 21% and 13% respectively; 26% of infections were previously undiagnosed. Black ethnicity (aRR 1.7, 95% CI 1.3-2.2, p<.001), lower level of education (aRR 1.4 for secondary level education, 95% CI 1.1-1.8, p=0.002), living with other HCW (aRR 1.2, 95% CI 1.0-1.4, p=0.007) were significantly associated with seropositivity. Having direct patient contact also carried a significant risk (being a healthcare assistant (aRR 1.8, 95% CI 1.3-2.3, p<.001), being a nurse (aRR 1.4, 95% CI 1.1-1.5, p=0.022), daily contact with COVID-19 patients (aRR 1.4, 95% CI 1.1-1.7, p=0.002), daily contact with patients without suspected or confirmed COVID-19 (aRR 1.3, 95% CI 1.1- 1.5, p=0.013) Breakthrough infection occurred in 23/4111(0.6%) of fully vaccinated participants; all had anti-S antibodies.
Conclusion The increase in seroprevalence reflects the magnitude of the third wave of the pandemic in Ireland. Genomic sequencing is needed to apportion risk to the workplace versus the household/community. Concerted efforts are needed to mitigate risk factors due to ethnicity and lower level of education, even at this stage of the pandemic. The undiagnosed and breakthrough infections call for ongoing infection prevention and control measures and testing of HCW in the setting of close contact. Vaccinated HCW with confirmed infection should be actively assessed, including SARS-CoV-2 whole genome sequencing (WGS), serology testing and assessment of host determinants, to advance understanding of the reasons for breakthrough infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Health Service Executive COVID-19 budget
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Office for Research Ethics Committee of Ireland gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵11 PRECISE Study (Prevalence of COVID-19 in Irish Healthcare Workers) Steering Group Members and Affiliations:
Dr. Lorraine Doherty, National Clinical Director for Health Protection, HSE-Health Protection Surveillance Centre (HPSC), Dublin, Ireland, and Chair of Steering Group, Dr. Niamh Allen, Consultant Physician in Infectious Diseases and Principal Investigator for PRECISE study, Professor Colm Bergin, Consultant Physician in Infectious Diseases and Site Lead for PRECISE study, St.James’s Hospital Dublin, Ireland, Dr. Niall Conlon, Consultant Immunologist, St. James’s Hospital, Dublin, Ireland, Dr Lisa Domegan, Surveillance Scientist, HSE-HPSC, Dublin, Ireland, Dr. Catherine Fleming, Consultant in Infectious Disease and Site Lead for PRECISE study, Galway University Hospital, Galway, Ireland, Dr Margaret Fitzgerald, National Public Health Lead. National Social Inclusion Office, Dublin, Ireland, Dr Cillian de Gascun, Director, UCD National Virus Reference Laboratory, University College Dublin, Dublin, Ireland, Joan Gallagher, Programme Manager, Office of the National Clinical Director for Health Protection, HSE HPSC, Dublin, Ireland, Dr. Derval Igoe, Specialist in Public Health Medicine, HSE HPSC, Dublin, 1, Ireland, Prof. Mary Keogan, Consultant Immunologist Beaumont Hospital & Clinical Lead, National Clinical Programme for Pathology, HSE, Ireland, Dr. Noirin Noonan, Consultant in Occupation Medicine, St. James’s Hospital, Dublin, Ireland., Professor Cliona O’Farrelly, Chair in Comparative Immunology, Trinity College Dublin, Ireland, Dr. Una Ni Riain, Consultant Microbiologist, Galway University Hospital, Galway, Ireland, Dr. Breda Smyth, Department of Public Health, HSE West, Ireland.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
